Organisation paid for research Program year 2025 Source: CMS Open Payments

Physicians East

Neither a doctor nor a teaching hospital

Research payments

$124,648

9 payments

Through program year 2025, Physicians East is reported as receiving $124,648 in research payments, across 9 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$60,476	3
2024	Research	$58,004	4
2019	Research	$6,169	2

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $80,022 4 payments
Eli Lilly and Company $41,354 4 payments
GlaxoSmithKline, LLC. $3,272 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM $42,888 1 payment
Ph2b Type 2 Diabetes $29,763 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $29,209 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $9,249 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) $7,370 1 payment
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlle $3,272 1 payment
A Prospective, Randomized, Double-Blind Comparison of Ly900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion $2,897 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.